Prognosis in Liver Transplantation Recipients after Hepatitis B Virus Recurrence

被引:6
|
作者
Jia, Zhongzhi [1 ]
Tian, Feng [1 ]
Li, Shaoqin [1 ]
Wang, Kai [1 ]
Zhao, Jinwei [1 ]
Wang, Yun [1 ]
Jiang, Liqiang [1 ]
Jiang, Guomin [1 ]
Li, Maoquan [2 ]
机构
[1] Nanjing Med Univ, Dept Intervent Radiog, Hosp Changzhou 2, Chang Zhou 213003, Jiangsu, Peoples R China
[2] Tongji Univ, Dept Intervent Radiol, Shanghai Peoples Hosp 10, Shanghai, Peoples R China
关键词
Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Omental artery; TRANSCATHETER ARTERIAL EMBOLIZATION; INTERNAL MAMMARY ARTERY; HEPATOCELLULAR-CARCINOMA; CYSTIC ARTERY; CHEMOEMBOLIZATION; BRANCHES;
D O I
10.5754/hge13755
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose: To evaluate the efficacy and safety of supplemental transcatheter arterial chemoembolization (TACE) through the extrahepatic collateral omental artery (OA) for hepatocellular carcinoma (HCC): Methods: We retrospective evaluated extrahepatic collateral OA on 34 patients, among 1826 patients with HCC who had undergone TACE. TACE of the OA was performed, and the dosage of emulsion was judged by tumor size and achievement of stagnant arterial flow. Results: Blood supply from the OA was demonstrated at the initial TACE in 7 patients, and after several TACE (mean 2.8th) sessions in 27 patients. The technical success rate was 100%. Total occlusion of the OA collatena was achieved in 85.3%. On one month later, complete, more than 50% and less than 50% uptake of iodized oil in the tumor were in 12, 16, and 6 patients, respectively. Alpha-fetoprotein level 1 month later was significantly lower than pre-procedure (P<0.05). There was no se rious complication that related to the ()mental embo lization. The cumulative survival rates at 6, 12 months were 94.1%, 85.3%, respectively. Conclusion: TACE of the OA is safe and reduce the incidence of post-TACE recurrence and/or residual of HCC, and could improve the therapeutic effect of TACE in the treatment of HCC.
引用
收藏
页码:2042 / 2046
页数:5
相关论文
共 50 条
  • [41] Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis
    Yamanaka, T
    Shiraki, K
    Nakazawa, S
    Okano, H
    Ito, T
    Deguchi, M
    Takase, K
    Nakano, T
    ANTICANCER RESEARCH, 2001, 21 (4B) : 2937 - 2940
  • [42] Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads
    Zhang, Lan
    Xie, Xiao-Ying
    Chen, Yi
    Ge, Ning-Ling
    Chen, Rong-Xin
    Gan, Yu-Hong
    Zhang, Bo-Heng
    Wang, Yan-Hong
    Ren, Zheng-Gang
    MEDICINE, 2017, 96 (52)
  • [43] Hepatitis B and hepatitis C viruses in liver transplantation
    Curry, MP
    TRANSPLANTATION, 2004, 78 (07) : 955 - 963
  • [44] Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis
    Katz, L. H.
    Paul, M.
    Guy, D. G.
    Tur-Kaspa, R.
    TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (04) : 292 - 308
  • [45] Analysis of S Gene Mutation of the Hepatitis B Virus in Adult Liver Transplant Recipients Showing Resistance to Hepatitis B Immunoglobulin Therapy
    Park, G-C.
    Hwang, S.
    Ahn, C-S.
    Kim, K-H.
    Moon, D-B.
    Ha, T. -Y.
    Song, G. -W.
    Jung, D-H.
    Shin, Y. W.
    Kim, S. -H.
    Chang, K. -H.
    Namgoong, J. -M.
    Park, C. -S.
    Park, H. -W.
    Park, Y-H.
    Kang, S. -H.
    Jung, B-H.
    Lee, S. -G.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (08) : 3047 - 3051
  • [46] Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China
    Tang, Jianxin
    Weng, Ruihui
    Fang, Taishi
    Zhang, Kangjun
    Yan, Xu
    Jin, Xin
    Xie, Linjie
    Zhao, Dong
    BMC INFECTIOUS DISEASES, 2024, 24 (01) : 383
  • [47] Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong
    Ma, Ka Wing
    Chok, Kenneth Siu Ho
    Fung, James Yan Yue
    Lo, Chung Mau
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2018, 6 (03) : 283 - 288
  • [48] The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study
    Zhang, Yaojun
    Huang, Junting
    Chen, Jinbin
    Yang, Keli
    Chen, Jiancong
    Xu, Li
    Zhou, Zhongguo
    Chen, Minshan
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 599 - 611
  • [49] The association between donor genetic variations in one-carbon metabolism pathway genes and hepatitis B recurrence after liver transplantation
    Lu, Di
    Zhuo, Jianyong
    Yang, Modan
    Wang, Chao
    Pan, Linhui
    Xie, Haiyang
    Xu, Xiao
    Zheng, Shusen
    GENE, 2018, 663 : 121 - 125
  • [50] 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation
    Duvoux, Christophe
    Belli, Luca S.
    Fung, James
    Angelico, Mario
    Buti, Maria
    Coilly, Audrey
    Cortesi, Paolo
    Durand, Francois
    Feray, Cyrille
    Fondevila, Constantino
    Lebray, Pascal
    Martini, Silvia
    Nevens, Frederik
    Polak, Wojciech G.
    Rizzetto, Mario
    Volpes, Riccardo
    Zoulim, Fabien
    Samuel, Didier
    Berenguer, Marina
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (05) : 583 - 605